Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon And Viatris Get CRL From FDA On Insulin Aspart

Biosimilar Rival To NovoLog Already Approved In Europe As Kixelle

Executive Summary

Viatris and partner Biocon have suffered a setback over their proposed insulin aspart biosimilar rival to NovoLog in the US, after the FDA issued a CRL relating to the filing.

You may also be interested in...



Biocon Receives Another FDA Setback On Insulin Aspart

Biocon has announced receipt of another CRL from the FDA relating to its insulin aspart biosimilar application, after the agency failed to schedule a reinspection of the firm’s Malaysia facility ahead of the latest goal date.

Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar

Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”

Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar

Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel